GLP1R and type 2 diabetes mellitus: Participants with type 2 diabetes who were fasting during Ramadan participated in the LIRA-Ramadan study, which compared the safety and effectiveness of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and sulphonylurea, a commonly prescribed diabetic drug, with those of the two other treatments.